Share This Article:

Dopamine and GABA Interaction in Basal Ganglia: GABA-A or GABA-B Receptor Stimulation Attenuates L-DOPA-Induced Striatal and Nigral ERK1/2 Signaling in a Rat Model of Parkinson’s Disease

Abstract Full-Text HTML XML Download Download as PDF (Size:375KB) PP. 479-488
DOI: 10.4236/jbbs.2013.36050    3,028 Downloads   5,219 Views   Citations

ABSTRACT

Parkinson’s disease (PD) is characterized by degeneration of nigrostriatal dopamine (DA) neurons. The primary drug used to treat PD symptoms is L-DOPA, but side effects such as dyskinesias limit its use. Previous findings show that L-DOPA treatment induces extracellular signal-regulated kinase (ERK1/2), a MAP-kinase protein. γ-aminobutyric acid (GABA) is intimately involved in basal ganglia function. Our previous study using a unilaterally lesioned rat model of PD indicated that elevating GABA levels by GABA transaminase inhibitor, aminooxyacetic acid significantly attenuated L-DOPA-induced ERK phosphorylation in the striatum and substantia nigra (SN). The aim of the present study was to assess the role of GABA-A and GABA-B receptor by using a selective agonists, muscimol and baclofen respectively, on L-DOPA-induced ERK phosphorylation in the striatum and SN. Unilaterally 6-OHDA-lesioned rats were prescreened by apomorphine induced rotation test for the extent of DA loss. Lesioned rats were treated with L-DOPA alone or after muscimol or baclofen pretreatment. Appropriate control groups were used. Phospho-ERK levels, tyrosine hydroxylase (to ascertain DA loss) and substance P (an indirect marker for DA loss) levels were assessed by immunohistochemistry using coronal slices at the level of striatum and SN. L-DOPA administration induced a robust increase (>300%) in phospho-ERK1/2 levels in the striatum and SN. Muscimol as well as baclofen pretreatment attenuated the L-DOPA-induced increase in phospho-ERK1/2 levels by >60% in the striatum and SN. Muscimol and baclofen pretreatment also greatly reduced the number of L-DOPA induced phospho-ERK1/2 stained cells in the striatum as well as the contralateral rotational behavior. The present data taken together with our previous study indicate that the L-DOPA induced increase in ERK1/2 is attenuated by GABA via a GABA-A and GABA-B receptor linked mechanism. The study provides further insight into a dopamine-GABA-ERK interaction in the therapeutic and/or side effects of L-DOPA in the basal ganglia.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Lynch and S. Sivam, "Dopamine and GABA Interaction in Basal Ganglia: GABA-A or GABA-B Receptor Stimulation Attenuates L-DOPA-Induced Striatal and Nigral ERK1/2 Signaling in a Rat Model of Parkinson’s Disease," Journal of Behavioral and Brain Science, Vol. 3 No. 6, 2013, pp. 479-488. doi: 10.4236/jbbs.2013.36050.

References

[1] C. R. Gerfen, “D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum: Animal Model of Parkinson’s Disease,” Neuroscientist, Vol. 9, No. 6, 2003, pp. 455-462.
http://dx.doi.org/10.1177/1073858403255839
[2] J. W. Mink, “The Basal Ganglia and Involuntary Movements: Impaired Inhibition of Competing Motor Patterns,” Archives of Neurology, Vol. 60, No. 10, 2003, pp. 1365-1368. http://dx.doi.org/10.1001/archneur.60.10.1365
[3] P. Hickey and M. Stacy, “Available and Emerging Treatments for Parkinson’s Disease: A Review,” Drug Design, Development, and Therapy, Vol. 5, 2011, pp. 241-254.
[4] C. R. Gerfen, “Molecular Effects of Dopamine on Striatal Projection Pathways,” Trends in Neurosciences, Vol. 23, 2000, pp. S64-S70.
[5] A. Berthet and E. Bezard, “Dopamine Receptors and L-Dopa-Induced Dyskinesia,” Parkinsonism & Related Disorders, Vol. 15, No. 4, 2009, pp. S8-12.
http://dx.doi.org/10.1016/S1353-8020(09)70827-2
[6] A. Nadjar, C. R. Gerfen and E. Bezard, “Priming for lDopa-Induced Dyskinesia in Parkinson’s Disease: A Feature Inherent to the Treatment or the Disease?” Progress in Neurobiology, Vol. 87, No. 1, 2009, pp. 1-9.
http://dx.doi.org/10.1016/j.pneurobio.2008.09.013
[7] C. R. Gerfen, S. Miyachi, R. Paletzki and P. Brown, “D1 Dopamine Receptor Supersensitivity in the DopamineDepleted Striatum Results from a Switch in the Regulation of ERK1/2/MAP Kinase,” Journal of Neuroscience, Vol. 22, No. 12, 2002, pp. 5042-5054.
[8] M. Feyder, A. Bonito-Oliva and G. Fisone, “L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission,” Frontiers in Behavioral Neuroscience, Vol. 5, 2011, p. 71.
[9] D. S. Kim, R. D. Palmiter, A. Cummins and C. R. Gerfen, “Reversal of Supersensitive Striatal Dopamine D1 Receptor Signaling and Extracellular Signal-Regulated Kinase Activity in Dopamine-Deficient Mice,” Neuroscience, Vol. 137, No. 4, 2006, pp. 1381-1388.
http://dx.doi.org/10.1016/j.neuroscience.2005.10.054
[10] J. E. Westin, L. Vercammen, E. M. Strome, C. Konradi, and M. A. Cenci, “Spatiotemporal Pattern of Striatal ERK1/2 Phosphorylation in a Rat Model of L-DOPA-Induced Dyskinesia and the Role of Dopamine D1 Receptors,” Biological Psychiatry, Vol. 62, No. 7, 2007, pp. 800-810. http://dx.doi.org/10.1016/j.biopsych.2006.11.032
[11] N. Pavon, A. B. Martin, A. Mendialdua and R. Moratalla, “ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice,” Biological Psychiatry, Vol. 59, No. 1, 2006, pp. 64-74.
http://dx.doi.org/10.1016/j.biopsych.2005.05.044
[12] E. Santini, E. Valjent, A. Usiello, M. Carta, A. Borgkvist, J. A. Girault, D. Herve, P. Greengard and G. Fisone, “Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in LDOPA-Induced Dyskinesia,” Journal of Neuroscience, Vol. 27, No. 26, 2007, pp. 6995-7005.
http://dx.doi.org/10.1523/JNEUROSCI.0852-07.2007
[13] M. A. Cenci, K. E. Ohlin and D. Rylander, “Plastic Effects of L-DOPA Treatment in the Basal Ganglia and Their Relevance to the Development of Dyskinesia,” Parkinsonism & Related Disorders, Vol. 15, No. 3, 2009, pp. S59-S63.
http://dx.doi.org/10.1016/S1353-8020(09)70782-5
[14] C. Moreno and S. Sivam, “The Time Course of D1 Agonist Induced Striatonigral ERK1/2 Signaling in a Rat Model of Parkinson’s Disease,” Journal of Behavioral and Brain Science, Vol. 2, No. 1, 2012, pp. 1-9.
http://dx.doi.org/10.4236/jbbs.2012.21001
[15] J. M. Tepper, E. D. Abercrombie and J. P. Bolam, “Basal Ganglia Macrocircuits,” Progress in Brain Research, Vol. 160, 2007, pp. 3-7.
http://dx.doi.org/10.1016/S0079-6123(06)60001-0
[16] A. Galvan and T. Wichmann, “GABAergic Circuits in the Basal Ganglia and Movement Disorders,” Progress in Brain Research, Vol. 160, 2007, pp. 287-312.
http://dx.doi.org/10.1016/S0079-6123(06)60017-4
[17] T. Trevitt, B. Carlson, M. Correa, A. Keene, M. Morales and J. D. Salamone, “Interactions between Dopamine D1 Receptors and Gamma-Aminobutyric Acid Mechanisms in Substantia Nigra Pars Reticulata of the Rat: Neurochemical and Behavioral Studies,” Psychopharmacology (Berl), Vol. 159, No. 3, 2002, pp. 229-237.
http://dx.doi.org/10.1007/s002130100908
[18] M. Ochi, S. Shiozaki and H. Kase, “L-DOPA-Induced Modulation of GABA and Glutamate Release in Substantia Nigra Pars Reticulata in a Rodent Model of Parkinson’s Disease,” Synapse, Vol. 52, No. 2, 2004, pp. 163-165. http://dx.doi.org/10.1002/syn.20006
[19] H. Wang, J. Katz, P. Dagostino and J. J. Soghomonian, “Unilateral 6-Hydroxydopamine Lesion of Dopamine Neurons and Subchronic L-DOPA Administration in the Adult Rat Alters the Expression of the Vesicular GABA Transporter in Different Subsets of Striatal Neurons and in the Substantia Nigra, Pars Reticulata,” Neuroscience, Vol. 145, No. 2, 2007, pp. 727-737.
http://dx.doi.org/10.1016/j.neuroscience.2006.12.001
[20] C. Rangel-Barajas, I. Silva, L. M. Lopez-Santiago, J. Aceves, D. Erlij and B. Floran, “L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Is Associated with Up-Regulation of Adenylyl Cyclase Type V/VI and Increased GABA Release in the Substantia Nigra Reticulata,” Neurobiology of Disease, Vol. 41, No. 1, 2011, pp. 51-61.
http://dx.doi.org/10.1016/j.nbd.2010.08.018
[21] F. Calon, M. Morissette, A. H. Rajput, O. Hornykiewicz, P. J. Bedard and T. Di Paolo, “Changes of GABA Receptors and Dopamine Turnover in the Postmortem Brains of Parkinsonians with Levodopa-Induced Motor Complications,” Movement Disorders, Vol. 18, No. 3, 2003, pp. 241-253. http://dx.doi.org/10.1002/mds.10343
[22] S. Lynch and S. P. Subbiah, “GABA Attenuates L-DOPA-Induced Striatal and Nigral ERK1/2 Signaling in a Rat Model of Parkinson’s Disease,” Journal of Behavioral and Brain Science, Vol. 3, No. 3, 2013, pp. 320-330.
http://dx.doi.org/10.4236/jbbs.2013.33032
[23] G. Paxinos and C. Watson, “The Rat Brain in Stereotaxic Coordinates,” 5th Edition, Elsevier Academic Press, New York, 2005.
[24] G. R. Breese, A. A. Baumeister, T. J. McCown, S. G. Emerick, G. D. Frye, K. Crotty and R. A. Mueller, “Behavior Differences between Neonatal and Adult 6-Hydrocydopamine-Treated Rats to Dopamine Agonists: Relevance to Neurological Symptoms in Clinical Syndromes with Reduced Brain Dopamine,” Journal of Pharmacology and Experimental Therapeutics, Vol. 231, 1984, pp. 343-354.
[25] M. Andersson, C. Konradi and M. A. Cenci, “cAMP Response Element-Binding Protein Is Required for Dopamine-Dependent Gene Expression in the Intact But Not the Dopamine-Denervated Striatum,” Journal of Neuroscience, Vol. 21, No. 24, 2001, pp. 9930-9943.
[26] M. Lebel, P. Robinson and M. Cyr, “Canadian Association of Neurosciences Review: The Role of Dopamine Receptor Function in Neurodegenerative Diseases,” Canadian Journal of Neurological Sciences, Vol. 34, No. 1, 2007, pp. 18-29.
[27] E. Santini, C. Alcacer, S. Cacciatore, M. Heiman, D. Herve, P. Greengard, J. A. Girault, E. Valjent and G. Fisone, “L-DOPA Activates ERK Signaling and Phosphorylates Histone H3 in the Striatonigral Medium Spiny Neurons of Hemiparkinsonian Mice,” Journal of Neurochemistry, Vol. 108, No. 3, 2009, pp. 621-633.
http://dx.doi.org/10.1111/j.1471-4159.2008.05831.x
[28] G. M. Thomas and R. L. Huganir, “MAPK Cascade Signalling and Synaptic Plasticity,” Nature Reviews Neuroscience, Vol. 5, No. 3, 2004, pp. 173-183.
http://dx.doi.org/10.1038/nrn1346
[29] C. R. Gerfen, R. Paletzki and P. Worley, “Differences between Dorsal and Ventral Striatum in Drd1a Dopamine Receptor Coupling of Dopamine and cAMP-Regulated Phosphoprotein-32 to Activation of Extracellular SignalRegulated Kinase,” Journal of Neuroscience, Vol. 28, No. 28, 2008, pp. 7113-7120.
http://dx.doi.org/10.1523/JNEUROSCI.3952-07.2008
[30] J. D. Berke, R. F. Paletzki, G. J. Aronson, S. E. Hyman and C. R. Gerfen, “A Complex Program of Striatal Gene Expression Induced by Dopaminergic Stimulation,” Journal of Neuroscience, Vol. 18, No. 14, 1998, pp. 5301-5310.
[31] A. Berthet, G. Porras, E. Doudnikoff, H. Stark, M. Cador, E. Bezard and B. Bloch, “Pharmacological Analysis Demonstrates Dramatic Alteration of D1 Dopamine Receptor Neuronal Distribution in the Rat Analog of L-DOPA-Induced Dyskinesia,” Journal of Neuroscience, Vol. 29, No. 15, 2009, pp. 4829-4835.
http://dx.doi.org/10.1523/JNEUROSCI.5884-08.2009
[32] E. Santini, E. Valjent and G. Fisone, “Parkinson’s Disease: Levodopa-Induced Dyskinesia and Signal Transduction,” FEBS Journal, Vol. 275, No. 7, 2008, pp. 1392-1399. http://dx.doi.org/10.1111/j.1742-4658.2008.06296.x
[33] E. Moreno, H. Hoffmann, M. Gonzalez-Sepulveda, G. Navarro, V. Casado, A. Cortes, J. Mallol, M. Vignes, P. J. McCormick, E. I. Canela, C. Lluis, R. Moratalla, S. Ferre, J. Ortiz and R. Franco, “Dopamine D1-Histamine H3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway,” Journal of Biological Chemistry, Vol. 286, No. 7, 2011, pp. 5846-5854.
http://dx.doi.org/10.1074/jbc.M110.161489
[34] J. Aceves, B. Floran, D. Martinez-Fong, A. Sierra, S. Hernandez and S. Mariscal, “L-DOPA Stimulates the Release of [3H]gamma-Aminobutyric Acid in the Basal Ganglia of 6-Hydroxydopamine Lesioned Rats,” Neuroscience Letters, Vol. 121, 1991, pp. 223-226.
http://dx.doi.org/10.1016/0304-3940(91)90690-U
[35] H. Ikeda, A. Kotani, N. Koshikawa and A. R. Cools,“Differential Role of GABAA and GABAB Receptors in Two Distinct Output Stations of the Rat Striatum: Studies on the Substantia Nigra Pars Reticulata and the Globus Pallidus,” Neuroscience, Vol. 167, No. 1, 2010, pp. 31-39.
http://dx.doi.org/10.1016/j.neuroscience.2010.01.054
[36] G. L. Snyder, G. Fisone and P. Greengard, “Phosphorylation of DARPP-32 Is Regulated by GABA in Rat Striatum and Substantia Nigra,” Journal of Neurochemistry, Vol. 63, No. 5, 1994, pp. 1766-1771.
http://dx.doi.org/10.1046/j.1471-4159.1994.63051766.x
[37] Y. Ding, L. Won, J. P. Britt, S. A. Lim, D. S. McGehee and U. J. Kang, “Enhanced Striatal Cholinergic Neuronal Activity Mediates L-DOPA-Induced Dyskinesia in Parkinsonian Mice,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, No. 2, 2011, pp. 840-845.
http://dx.doi.org/10.1073/pnas.1006511108
[38] E. Santini, M. Feyder, G. Gangarossa, H. S. Bateup, P. Greengard and G. Fisone, “Dopamineand cAMP-Regulated Phosphoprotein of 32 KDa (DARPP-32)-Dependent Activation of ERK and Mammalian Target of Rapamycin Complex 1 (TORC1) Signaling in Experimental Parkinsonism,” Journal of Biological Chemistry, Vol. 287, , 2012, pp. 27806-27812.
http://dx.doi.org/10.1074/jbc.M112.388413
[39] J. Boyes, and J. P. Bolam, “Localization of GABA Receptors in the Basal Ganglia,” Progress in Brain Research, Vol. 160, 2007, pp. 229-243.
http://dx.doi.org/10.1016/S0079-6123(06)60013-7
[40] T. Wichmann, M. A. Kliem and M. R. DeLong, “Antiparkinsonian and Behavioral Effects of Inactivation of the Substantia Nigra Pars Reticulata in Hemiparkinsonian Primates,” Experimental Neurology, Vol. 167, No. 2, 2001, pp. 410-424. http://dx.doi.org/10.1006/exnr.2000.7572
[41] B. B. Carlson, S. Behrstock, A. J. Tobin and J. D. Salamone, “Brain Implantations of Engineered GABA-Re-leasing Cells Suppress Tremor in an Animal Model of Parkinsonism,” Neuroscience, Vol. 119, No. 4, 2003, pp. 927-932. http://dx.doi.org/10.1016/S0306-4522(03)00218-5
[42] C. C. Tenn and L. P. Niles, “Mechanisms Underlying the Antidopaminergic Effect of Clonazepam and Melatonin in Striatum,” Neuropharmacology, Vol. 36, No. 11-12, 1997, pp. 1659-1663.
http://dx.doi.org/10.1016/S0028-3908(97)00165-2
[43] C. Winkler, C. Bentlage, G. Nikkhah, M. Samii and A. Bjorklund, “Intranigral Transplants of GABA-Rich Striatal Tissue Induce Behavioral Recovery in the Rat Parkinson Model and Promote the Effects Obtained by Intrastriatal Dopaminergic Transplants,” Experimental Neurology, Vol. 155, No. 2, 1999, pp. 165-186.
http://dx.doi.org/10.1006/exnr.1998.6916
[44] R. A. Hauser, J. P. Hubble and D. D. Truong, “Randomized Trial of the Adenosine A2A Receptor Antagonist Istradefylline in Advanced PD,” Neurology, Vol. 61, No. 3, 2003, pp. 297-303.
http://dx.doi.org/10.1212/01.WNL.0000081227.84197.0B
[45] H. Kase, S. Aoyama, M. Ichimura, K. Ikeda, A. Ishii, T. Kanda, K. Koga, N. Koike, M. Kurokawa, Y. Kuwana, A. Mori, J. Nakamura, H. Nonaka, M. Ochi, M. Saki, J. Shimada, T. Shindou, S. Shiozaki, F. Suzuki, M. Takeda, K. Yanagawa, P. J. Richardson, P. Jenner, P. Bedard, E. Borrelli, R. A. Hauser and T. N. Chase, “Progress in Pursuit of Therapeutic A2A Antagonists: The Adenosine A2A Receptor Selective Antagonist KW6002: Research and Development toward a Novel Nondopaminergic Therapy for Parkinson’s Disease,” Neurology, Vol. 61, No. 11, Suppl. 6, 2003, pp. S97-S100.
http://dx.doi.org/10.1212/01.WNL.0000095219.22086.31
[46] P. Jenner, “Istradefylline, a Novel Adenosine A2A Receptor Antagonist, for the Treatment of Parkinson’s Disease,” Expert Opinion on Investigational Drugs, Vol. 14, No. 6, 2005, pp. 729-738.
http://dx.doi.org/10.1517/13543784.14.6.729
[47] A. Pinna, J. Wardas, N. Simola and M. Morelli, “New Therapies for the Treatment of Parkinson’s Disease: Adenosine A2A Receptor Antagonists,” Life Sciences, Vol. 77, No. 26, 2005, pp. 3259-3267.
http://dx.doi.org/10.1016/j.lfs.2005.04.029
[48] J. M. Savola, M. Hill, M. Engstrom, H. Merivuori, S. Wurster, S. G. McGuire, S. H. Fox, A. R. Crossman and J. M. Brotchie, “Fipamezole (JP-1730) Is a Potent Alpha2 Adrenergic Receptor Antagonist that Reduces Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson’s Disease,” Movement Disorders, Vol. 18, No. 8, 2003, pp. 872-883.
http://dx.doi.org/10.1002/mds.10464
[49] M. Ochi, S. Shiozaki and H. Kase, “Adenosine A2A Receptor-Mediated Modulation of GABA and Glutamate Release in the Output Regions of the Basal Ganglia in a Rodent Model of Parkinson’s Disease,” Neuroscience, Vol. 127, No. 1, 2004, pp. 223-231.
http://dx.doi.org/10.1016/j.neuroscience.2004.04.050

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.